Orchestra BioMed

Historical price data

Orchestra BioMed is a clinical-stage medical device innovator focused on developing and commercializing high-impact therapeutic solutions for hypertension and atherosclerotic artery disease. The company's strategy centers on a capital-efficient, partnership-enabled model to de-risk development and leverage the commercial infrastructure of established partners. Its late-stage pipeline features two flagship platforms: AVIM Therapy, a bioelectronic treatment for hypertension delivered via pacemakers, and Virtue® SAB, a drug/device combination for treating artery disease without a permanent implant.

Two late-stage therapeutic platforms: 1) AVIM Therapy, a bioelectronic treatment for hypertension delivered via modified pacemakers, and 2) Virtue® SAB, a drug/device combination using a proprietary infusion balloon to deliver extended-release sirolimus without a permanent implant.